Dualitybio Inc.
Clinical trials sponsored by Dualitybio Inc., explained in plain language.
-
New hope for advanced breast cancer: DB-1303 takes on T-DM1
Disease control OngoingThis phase 3 study compares a new drug, DB-1303, to the current standard T-DM1 in 228 adults with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. All participants have already been treated with trastuzumab and a taxane. The …
Phase: PHASE3 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 22, 2026 11:55 UTC
-
New hope for Hard-to-Treat cancers: DB-1305 enters human trials
Disease control OngoingThis study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 18, 2026 11:50 UTC
-
New hope for hard-to-treat breast cancer: targeted drug takes on chemo in major trial
Disease control OngoingThis study tests a new drug, DB-1303, against standard chemotherapy in about 540 people with a specific type of advanced breast cancer (HER2-low, hormone receptor-positive) that has stopped responding to hormone therapy. The main goal is to see if DB-1303 can delay cancer growth …
Phase: PHASE3 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 17, 2026 12:08 UTC